NasdaqCM - Delayed Quote USD

RenovoRx, Inc. (RNXT)

1.3300 -0.1600 (-10.74%)

At close: October 30 at 4:00:00 PM EDT

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

RenovoRx to Participate at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum

GlobeNewswire 3d ago

RNXT
-10.74%
RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

GlobeNewswire 9d ago

RNXT
-10.74%
RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial

GlobeNewswire 24d ago

RNXT
-10.74%
RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

GlobeNewswire 2mo ago

RNXT
-10.74%
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

GlobeNewswire 2mo ago

RNXT
-10.74%
^IXIC
RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers

MarketBeat 2mo ago

RNXT
-10.74%
RenovoRx Inc (RNXT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Expansion ...

GuruFocus.com 2mo ago

RNXT
-10.74%
RenovoRx Q2 Earnings Call Highlights

MarketBeat 2mo ago

RNXT
-10.74%
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates

Zacks 2mo ago

RNXT
-10.74%
RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer

GlobeNewswire 2mo ago

RNXT
-10.74%
RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors

GlobeNewswire 2mo ago

RNXT
-10.74%
RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th

GlobeNewswire 2mo ago

RNXT
-10.74%

Performance Overview

Return	RNXT	S&P 500 (^GSPC)
YTD	+58.33%	+10.73%
1-Year	+31.03%	+11.11%
3-Year	+33.00%	+81.91%

U.S. markets closed

RenovoRx, Inc. (RNXT)

RenovoRx to Participate at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum

RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers

RenovoRx Inc (RNXT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Expansion ...

RenovoRx Q2 Earnings Call Highlights

RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates

RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer

RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors

RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th